The dsDNA and Anti-dsDNA Antibody

DNA, or deoxyribonucleic acid, is a fundamental molecule that carries the genetic information of living organisms. Its double-stranded form, known as dsDNA, plays a crucial role in various biological processes. Understanding the intricacies of dsDNA and its interaction with anti-dsDNA antibodies is essential for comprehending autoimmune diseases and advancing diagnostic and therapeutic strategies.

Browse all dsDNA products

Background of Anti-dsDNA Antibodies

Unveiling Anti-dsDNA Antibodies

Anti-dsDNA antibodies are a class of autoantibodies that specifically recognize and target dsDNA molecules. These antibodies are produced by the immune system, particularly B cells, as a defense mechanism against foreign substances. However, in certain autoimmune diseases, such as systemic lupus erythematosus (SLE), the immune system mistakenly attacks self-components, leading to the production of anti-dsDNA antibodies.

Clinical Significance of Anti-dsDNA Antibodies

The clinical significance of anti-dsDNA antibodies lies primarily in their association with systemic lupus erythematosus (SLE), a chronic autoimmune disease characterized by inflammation and damage to multiple organs and tissues. In fact, the detection of anti-dsDNA antibodies is one of the diagnostic criteria for SLE. These antibodies are highly specific to SLE and their presence can aid in distinguishing it from other autoimmune disorders.

Detection of Anti-dsDNA Antibodies

Various methods can be used to detect and measure anti-dsDNA antibodies, although there is no universally accepted standard test for diagnosis, and different methods may yield inconsistent results.

• The Farr assay is a specific test that quantifies the amount of anti-dsDNA antibodies by precipitating antigen-antibody complexes using ammonium sulfate. It utilizes radioactively labeled dsDNA to determine antibody levels, but its complexity and use of radioactive materials limit its routine use in diagnostic laboratories.
• The polyethylene glycol (PEG) assay precipitates DNA-antibody complexes, allowing for the detection of both high and low-avidity anti-dsDNA antibodies.
• Immunofluorescence methods involve the use of different substrates to identify anti-dsDNA antibodies. Animal tissue, such as liver and kidney sections, was previously used but has been largely replaced by HEp-2 cells. HEp-2 cells, derived from a laryngeal carcinoma, provide better differentiation of ANA patterns due to their large nuclei and high mitotic rate. Incubating serum with HEp-2 cells and fluorescent-labeled antibodies enables the visualization of specific staining patterns.
• Enzyme immunoassay (EIA) involves using a DNA-coated microplate to detect antibodies. The DNA used can be recombinant dsDNA or extracted from the calf thymus. The binding of anti-dsDNA antibodies to the DNA on the microplate is visualized using enzyme-linked secondary antibodies. EIA can provide quantitative or semi-quantitative results but may yield false positives due to ssDNA contamination.
• Flow cytometry and multiplex immunoassay (MIA) employ coated beads with multiple autoantigens, including dsDNA, for the detection of ANA. In the presence of anti-dsDNA antibodies, fluorescent-labeled secondary antibodies bind to the antibodies on the beads, and flow cytometry or automated analysis allows for detection.
• Microarrays are a new method that involves depositing individual autoantigens on a surface, allowing simultaneous screening for multiple autoimmune diseases. If anti-dsDNA antibodies are present, they bind to the corresponding autoantigens, and fluorescent-labeled anti-IgG antibodies visualize the binding pattern.

dsDNA-Related Antibodies

dsDNA-Antigens

dsDNA-Related ELISA Kits